Cowen Upgrades Exelixis (EXEL) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Exelixis (EXEL) Tops Q3 EPS by 5c
November 4, 2014 4:54 PM ESTExelixis (NASDAQ: EXEL) reported Q3 EPS of ($0.32), $0.05 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $6.3 million versus the consensus estimate of $6.77 million.
For earnings history and earnings-related data on Exelixis (EXEL) click here.
... MoreExelixis, Inc. (EXEL) Reports Top-Line Results From a Phase 2 Trial of Cabozantinib
November 4, 2014 4:21 PM ESTExelixis, Inc. (NASDAQ: EXEL) today announced positive top-line results from a randomized phase 2 trial of cabozantinib and erlotinib alone or in combination as second- or third-line therapy in patients with stage IV EGFR wild-type non-small cell lung cancer (NSCLC). This trial (Study E1512) is sponsored by the U.S. National Cancer Institute (NCI) through a Cooperative Research and Development Agreement between the Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment and Diagnosis, NCI and Exelixis. Study E1512 was designed and is being conducted by the ECOG-ACRIN Cancer Research Group as part of Exelixis... More
